There is a political fight building within MAGA that is so divisive that the movement’s “crackup” could finally be here once and for all. This is according to Bulwark White House Correspondent Andrew Egger, who on Friday explained that no matter how President Donald Trump decides to handle the matter, it’s likely to result in the fracturing of his coalition.
With the Democratic majority taking control of Congress in just six weeks, Trump and the GOP are desperate to confirm last-minute nominees. But over the past week, a handful of such nominees were slapped down not by Democrats, but by Republican defectors who are leaving office at the end of the term and don’t appear to be going quietly. Then Trump himself withdrew the nomination of Heidi Overton for Commissioner of the FDA, and according to Egger, the reason for said nominee’s unviability speaks to an issue that is breaking MAGA apart.
“Last year, it was rare to see a figure like Overton go down without even a vote,” writes Egger. “Her MAGA credentials are strong: She’s a longtime Trump health-policy official who worked on health care issues at the America First Policy Institute during the president’s interregnum and has spent the last two years in a key role on the White House Domestic Policy Council. As tensions between MAGA and MAHA grew over the last year, Overton was as much of an internal peacemaker as any — crucial in mediating fights between HHS Secretary Robert F. Kennedy Jr. and Agriculture Secretary Brooke Rollins.” But in the end, rather than uniting warring MAGA factions, her nomination was torn apart by them. According to Egger, “The MAHA faithful mistrusted her as ‘controlled opposition’ who would work to neuter RFK Jr.’s agenda from the inside, while MAHA skeptics like Sen. Bill Cassidy worried she would work to further Kennedy’s plans to disrupt childhood vaccines.”
What’s more, she represented another coalition-shaking controversy: the fight over how the FDA will handle abortion policy. While anti-abortion activists were a key part of Trump’s coalition in 2016, after 2024, explains Egger, many pro-lifers were angered by the president’s move to the center on the issue. Now, they’re waiting to see whether Trump’s FDA will do anything to restrict the sale of the abortion drug mifepristone by mail, which could be done without congressional legislation. According to Egger, the Trump administration has attempted to play both sides of the debate, but MAGA pro-lifers are getting tired of waiting. This has played out in the halls of Congress, asserted Sen. Bill Cassidy (R-LA), as pro-life senators were holding out on Overton’s nomination because they wanted assurances that the next FDA commissioner would move to restrict mifepristone.
“Whichever way the FDA rules spells further danger for Trump and his coalition,” Egger concludes. “After two cycles where abortion politics proved highly favorable for Democrats, the issue all but dropped out of voters’ minds in 2026. But a crackdown on mifepristone would bring it back into the spotlight — while a failure to crack down could prove the final straw for a diminished but highly loyal faction of single-issue Trump voters.”